Understanding how reduced oxidative stress affects lung cancer growth and spread
Elucidating Thiol Reductive Stress in Lung Cancer Growth and Metastasis
['FUNDING_CAREER'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-11031658
This study is looking at how a certain type of stress in lung cancer, especially in non-small cell lung cancers, might affect how the cancer grows and spreads, and it aims to find new ways to treat it by identifying genes that could make cancer cells more sensitive to this stress.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11031658 on ClinicalTrials.gov |
What this research studies
This research investigates the role of reductive stress in lung cancer, particularly focusing on non-small cell lung cancers (NSCLCs). It aims to understand how an overly reductive environment within tumors can influence cancer growth and metastasis. The study utilizes advanced techniques, including CRISPR screening, to identify specific genes that may make certain cancer cells more vulnerable to this type of stress. By examining the balance of key metabolic processes, the research seeks to uncover new therapeutic targets for treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with specific genetic profiles related to NRF2 and KEAP1.
Not a fit: Patients with other types of lung cancer or those without the specific genetic markers being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that specifically target vulnerabilities in lung cancer cells, potentially improving patient outcomes.
How similar studies have performed: While the approach of studying reductive stress in cancer is relatively novel, preliminary findings suggest that targeting metabolic vulnerabilities in cancer cells has shown promise in other studies.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GE, MAOLIN — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: GE, MAOLIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer cell line, cancer metastasis, Cancer Model, Cancer Patient, CancerModel